- Home
- IMO vs ARGX Comparison
IMO vs ARGX Comparison
Compare IMO & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMO
- ARGX
- Stock Information
- Founded
- IMO 1880
- ARGX 2008
- Country
- IMO Canada
- ARGX Netherlands
- Employees
- IMO N/A
- ARGX N/A
- Industry
- IMO Integrated oil Companies
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMO Energy
- ARGX Health Care
- Exchange
- IMO Nasdaq
- ARGX Nasdaq
- Market Cap
- IMO 35.0B
- ARGX 37.3B
- IPO Year
- IMO N/A
- ARGX 2017
- Fundamental
- Price
- IMO $70.25
- ARGX $650.39
- Analyst Decision
- IMO Hold
- ARGX Strong Buy
- Analyst Count
- IMO 2
- ARGX 20
- Target Price
- IMO $110.00
- ARGX $653.11
- AVG Volume (30 Days)
- IMO 564.6K
- ARGX 252.7K
- Earning Date
- IMO 01-31-2025
- ARGX 02-27-2025
- Dividend Yield
- IMO 2.44%
- ARGX N/A
- EPS Growth
- IMO 2.39
- ARGX N/A
- EPS
- IMO 6.76
- ARGX N/A
- Revenue
- IMO $38,358,192,368.00
- ARGX $1,908,659,000.00
- Revenue This Year
- IMO $4.54
- ARGX $70.98
- Revenue Next Year
- IMO $6.44
- ARGX $51.22
- P/E Ratio
- IMO $10.43
- ARGX N/A
- Revenue Growth
- IMO N/A
- ARGX 85.56
- 52 Week Low
- IMO $55.82
- ARGX $349.86
- 52 Week High
- IMO $80.17
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- IMO 60.37
- ARGX 57.29
- Support Level
- IMO $67.17
- ARGX $635.85
- Resistance Level
- IMO $72.09
- ARGX $655.52
- Average True Range (ATR)
- IMO 1.80
- ARGX 15.67
- MACD
- IMO 0.95
- ARGX -1.53
- Stochastic Oscillator
- IMO 82.85
- ARGX 54.50
About IMO Imperial Oil Limited
Imperial Oil Ltd is one of Canada's largest integrated oil companies. It is active in all phases of the petroleum industry in Canada, including the exploration for, and production and sale of, crude oil and natural gas. It is a major producer of crude oil, the largest petroleum refiner, a leading marketer of petroleum products, and a major producer of petrochemicals. The company also pursues lower-emission business opportunities including carbon capture and storage, hydrogen and lower-emission fuels. The company's operations are conducted in three main segments: Upstream, Downstream, and Chemical. The majority of revenue is from the downstream segment. The Downstream segment is organized and operates to refine crude oil into petroleum products and to distribute and market these products.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.